Advances in mechanisms of allergy

Journal of Allergy and Clinical Immunology

Volumn 111, Issue SUPPL. 3, 2003, Pages

  Bochner, Bruce S ^a   Hamid, Qutayba ^b  

^a JOHNS HOPKINS ASTHMA AND ALLERGY CENTER   (United States)

^b MCGILL UNIVERSITY   (Canada)

Author keywords

Airway hyperreactivity; Anaphylaxis; Basophils; Chemokines; CpGS; Cytokines; Eosinophils; Epithelial cells; Mast cells; Mouse models; T cells

Indexed keywords

ALPHA INTERFERON; CHEMOKINE RECEPTOR; CYTOKINE; ENDOTOXIN; FC RECEPTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HYDROXYUREA; IMATINIB; IMMUNOGLOBULIN E; INTERLEUKIN 13; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 5 ANTIBODY; LEUKOTRIENE D4; MESSENGER RNA; OLIGODEOXYNUCLEOTIDE; OVALBUMIN;

ALLERGY; ANAPHYLAXIS; ANIMAL MODEL; BASOPHIL; BRONCHUS HYPERREACTIVITY; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; CPG ISLAND; EOSINOPHIL; EPITHELIUM CELL; HEMATOPOIESIS; HUMAN; HYPEREOSINOPHILIA; HYPEREOSINOPHILIC SYNDROME; KNOCKOUT MOUSE; LUNG LAVAGE; MAST CELL; MOUSE; NONHUMAN; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE;

EID: 0037338912     PISSN: 00916749     EISSN: None     Source Type: Journal    
DOI: 10.1067/mai.2003.149     Document Type: Review

References (47)

1. Altman LC, Munk Z, Seltzer J, Noonan N, Shingo S, Zhang J, et al. A placebo-controlled, dose-ranging study of montelukast, a cysteinyl leukotriene-receptor antagonist, Montelukast Asthma Study Group. J Allergy Clin Immunol 1998;102:50-6.
2. Braccioni F, Dorman SC, O'Byrne PM, Inman MD, Denburg JA, Parameswaran K, et al. The effect of cysteinyl leukotrienes on growth of eosinophil progenitors from peripheral blood and bone marrow of atopic subjects. J Allergy Clin Immunol 2002;110:96-101.
3. Nagata M, Saito K, Tsuchiya K, Sakamoto T. Leukotriene D4 upregulates eosinophil adhesion via the cysteinyl leukotriene 1 receptor. J Allergy Clin Immunol 2002;109:676-80.
4. Bandeira-Melo C, Hall JC, Penrose JF, Weller PF. Cysteinyl leukotrienes induce IL-4 release from cord blood-derived human eosinophils. J Allergy Clin Immunol 2002;109:975-9.
5. Leckie MJ, Brinke A, Khan J, Diamant Z, O'Connor BJ, Walls CM, et al. Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response. Lancet 2000;356:2144-8.
6. Flood-Page PT, Menzies-Gow AN, Kay B, Robinson DS. Eosinophil's role remains uncertain as anti-interleukin-5 only partially depletes eosinophils from asthmatic airway tissue. Am J Respir Crit Care Med 2003;167:199-204.
7. Gleich GJ, Leiferman KM, Pardanani A, Tefferi A, Butterfield JH. Treatment of hypereosinophilic syndrome with imatinib mesylate. Lancet 2002;359:1577-8.
8. Ault P, Cortes J, Koller C, Kaled ES, Kantarjian H. Response of idiopathic hypereosinophilic syndrome to treatment with imatinib mesylate. Leuk Res 2002;26:881-4.
9. Savage DG, Antman KH. Imatinib mesylate - a new oral targeted therapy. N Engl J Med 2002;346:683-93.
10. Yu C, Cantor AB, Yang H, Browne C, Wells RA, Fujiwara Y, et al. Targeted deletion of a high-affinity GATA-binding site in the GATA-1 promoter leads to selective loss of the eosinophil lineage in vivo. J Exp Med 2002;195:1387-95.
11. Hartnell A, Kay AB, Wardlaw AJ. IFN-gamma induces expression of FcγRIII (CD16) on human eosinophils. J Immunol 1992;148:1471-8.
12. Zhu XD, Hamann KJ, Munoz NM, Rubio N, Mayer D, Hernrreiter A, et al. Intracellular expression of FcγRIII (CD16) and its mobilization by chemoattractants in human eosinophils. J Immunol 1998;161:2574-9.
13. Davoine F, Lavigne S, Chakir J, Ferland C, Boulay M-É, Laviolette M. Expression of FcγRIII (CD16) on human peripheral blood eosinophils increases in allergic conditions. J Allergy Clin Immunol 2002;109:463-9.
14. Bochner BS. Road signs guiding leukocytes along the inflammation superhighway. J Allergy Clin Immunol 2000;106:817-28.
15. Bochner BS, Schleimer RP. Mast cells, basophils, and eosinophils: distinct but overlapping pathways for recruitment. Immunol Rev 2001;179:5-15.
16. Ma W, Bryce PJ, Humbles AA, Laouini D, Yalcindag A, Alenius H, et al. CCR3 is essential for skin eosinophilia and airway hyperresponsiveness in a murine model of allergic skin inflammation. J Clin Invest 2002;109:621-8.
17. Humbles AA, Lu B, Friend DS, Okinaga S, Lora J, Al-Garawi A, et al. The murine CCR3 receptor regulates both the role of eosinophils and mast cells in allergen-induced airway inflammation and hyperresponsiveness. Proc Natl Acad Sci U S A 2002;99:1479-84.
18. Nagase H, Kudo K, Izumi S, Ohta K, Kobayashi N, Yamaguchi M, et al. Chemokine receptor expression profile of eosinophils at inflamed tissue sites: decreased CCR3 and increased CXCR4 expression by lung eosinophils. J Allergy Clin Immunol 2001;108:563-9.
19. Dunzendorfer S, Kaneider NC, Kaser A, Woell E, Frade JMR, Mellado M, et al. Functional expression of chemokine receptor 2 by normal human eosinophils. J Allergy Clin Immunol 2001;108:581-7.
20. Hirai H, Tanaka K, Yoshie O, Ogawa K, Kenmotsu K, Takamori Y, et al. Prostaglandin D2 selectively induces chemotaxis in T helper type 2 cells, eosinophils, and basophils via seven-transmembrane receptor CRTH2. J Exp Med 2001;193:255-61.
21. Gervais FG, Cruz RPG, Chateanuneuf A, Gale S, Sawyer N, Nantel F, et al. Selective modulation of chemokinesis, degranulation, and apoptosis in eosinophils through the PGD2 receptors CRTH2 and DP. J Allergy Clin Immunol 2001;108:982-8.
22. Matsuoka T, Hirata M, Tanaka H, Takahashi Y, Murata T, Kabashima K, et al. Prostaglandin D2 as a mediator of allergic asthma. Science 2000;287:2013-7.
23. Foster B, Schwartz LB, Devouassoux G, Metcalfe DD, Prussin C. Characterization of mast-cell tryptase-expressing peripheral blood cells as basophils. J Allergy Clin Immunol 2002;109:287-93.
24. Bochner BS. Systemic activation of basophils and eosinophils: markers and consequences. J Allergy Clin Immunol 2000;106:S292-S302.
25. Matsumoto K, Appiah-Pippim J, Schleimer RP, Bickel CA, Beck LA, Bochner BS. CD44 and CD69 represent different types of cell surface activation markers for human eosinophils. Am J Respir Cell Mol Biol 1998;18:860-6.
26. Yoshimura C, Yamaguchi M, Iikura M, Izumi S, Kudo K, Nagase H, et al. Activation markers of human basophils: CD69 expression is strongly and preferentially induced by IL-3. J Allergy Clin Immunol 2002;109:817-23.
27. Hauswirth AW, Natter S, Ghannadan M, Majlesi Y, Schernthaner G-H, Sperr WR, et al. Recombinant allergens promote expression of CD203c on basophils in sensitized individuals. J Allergy Clin Immunol 2002;110:102-9.
28. Vonakis BM, Gibbons S, Jr. Sora R, Langdon JM, MacDonald SM. Src homology 2 domain-containing inositol 5′ phosphatase is negatively associated with histamine release to human recombinant histamine-releasing factor in human busophils. J Allergy Clin Immunol 2001;108:822-31.
29. Schroeder JT, Miura K, Kim H-H, Sin A, Cianferoni A, Casolaro V. Selective expression of nuclear factor of activated T cells 2/c1 in human basophils: evidence for involvement in IgE-mediated IL-4 generation. J Allergy Clin Immunol 2002;109:507-13.
30. Sexton DW, Blaylock MG, Walsh GM. Human alveolar epithelial cells engulf apoptotic eosinophils by means of integrin- and phosphatidylserine receptor-dependent mechanisms: a process upregulated by dexamethasone. J Allergy Clin Immunol 2001;108:962-9.
31. Bureau F, Seumois G, Jaspar F, Vanderplasschen A, Detry B, Pastoret P-P, et al. CD40 engagement enhances eosinophil survival through induction of cellular inhibitor of apoptosis protein 2 expression: possible involvement in allergic inflammation. J Allergy Clin Immunol 2002;110:443-9.
32. Wedi B, Wieczorek D, Sttinkel T, Breuer K, Kapp A. Staphylococcal exotoxins exert proinflammatory effects through inhibition of eosinophil apoptosis, increased surface antigen expression (CD11b, CD45, CD54, and CD69), and enhanced cytokine-activated oxidative burst, thereby triggering allergic inflammatory reactions. J Allergy Clin Immunol 2002;109:477-84.
33. Temple R, Allen E, Fordham J, Phipps S, Schneider HC, Lindauer K, et al. Microarray analysis of eosinophils reveals a number of candidate survival and apoptosis genes. Am J Respir Cell Mol Biol 2001;25:425-33.
34. Pope SM, Brandt EB, Mishra A, Hogan SP, Zimmermann N, Matthaei KI, et al. IL-13 induces eosinophil recruitment into the lung by an IL-5- and eotaxin-dependent mechanism. J Allergy Clin Immunol 2001;108:594-601.
35. Suzuki M, Maghni K, Molet S, Shimbara A, Hamid QA, Martin JG. IFN-gamma secretion by CD8T cells inhibits allergen-induced airway eosinophilia but not late airway responses. J Allergy Clin Immunol 2002;109:803-9.
36. Tomkinson A, Duez C, Lahn M, Gelfand EW. Adoptive transfer of T cells induces airway hyperresponsiveness independently of airway eosinophilia but in a signal transducer and activator of transcription 6-dependent manner. J Allergy Clin Immunol 2002;109:810-6.
37. Tomkinson A, Kanehiro A, Rabinovitch N, Joetham A, Cieslewicz G, Gelfand EW. The failure of STAT6-deficient mice to develop airway eosinophilia and airway hyperresponsiveness is overcome by interleukin-5. Am J Respir Crit Care Med 1999;160:1283-91.
38. Oettgen HC, Martin TR, Wynshaw-Boris A, Deng C, Draze JM, Leder P. Active anaphylaxis in IgE-deficient mice. Nature 1994;370:367-70.
39. Miyajima I, Dombrowicz D, Martin TR, Ravetch JV, Kinet JP, Galli SJ. Systemic anaphylaxis in the mouse can be mediated largely through IgG1 and Fc gammaRIII. Assessment of the cardiopulmonary changes, mast cell degranulation, and death associated with active or IgE- or IgG1-dependent passive anaphylaxis. J Clin Invest 1997;99:901-14.
40. Dombrowicz D, Flamand V, Brigman KK, Koller BH, Kinet JP. Abolition of anaphylaxis by targeted disruption of the high affinity immunoglobulin E receptor alpha chain gene. Cell 1993;75:969-76.
41. Strait RT, Morris SC, Yang M, Qu XW, Finkelman FD. Pathways of anaphylaxis in the mouse. J Allergy Clin Immunol 2002;109:658-68.
42. Gerhold K, Blumchen K, Bock A, Seib C, Stock P, Kallinich T, et al. Endotoxins prevent murine IgE production, T(H)2 immune responses. and development of airway eosinophilia but not airway hyperreactivity. J Allergy Clin Immunol 2002; 110.
43. Tighe H, Takabayashi K, Schwartz D, Van Nest G, Tuck S, Eiden JJ, et al. Conjugation of immunostimulatory DNA to the short ragweed allergen amb a 1 enhances its immunogenicity and reduces its allergenicity. J Allergy Clin Immunol 2000;106:124-34.
44. Marshall JD, Abtahi S, Eiden JJ, Tuck S, Milley R, Haycock F, et al. Immunostimulatory sequence DNA linked to the Amb a 1 allergen promotes T(H)1 cytokine expression while downregulating T(H)2 cytokine expression in PBMCs from human patients with ragweed allergy. J Allergy Clin Immunol 2001;108:191-7.
45. Santeliz JV, Van Nest G, Traquina P, Larsen E, Wills-Karp M. Amb a 1-linked CpG oligodeoxynucleotides reverse established airway hyperresponsiveness in a murine model of asthma. J Allergy Clin Immunol 2002;109:455-62.
46. Luccioli S, Brody DT, Hasan S, Keane-Myers A, Prussin C, Metcalfe DD. IgE(+). Kit(-). I-A/I-E(-) myeloid cells are the initial source of IL-4 after antigen challenge in a mouse model of allergic pulmonary inflammation. J Allergy Clin Immunol 2002;110:117-24.
47. Gelfand EW, Cui ZH, Takeda K, Kanehiro A, Joetham A. Fexofenadine modulates T-cell function, preventing allergen-induced airway inflammation and hyperresponsiveness. J Allergy Clin Immunol 2002;110:85-95.